Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)

September 25, 2024 7:14 AM UTC Send to a Friend
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $344.00 price target on Amgen (NASDAQ: AMGN).The analyst commented, "Remain ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login